Blog

Jonathan A. Nowak: KRAS G12C mutations are predictive of response in CRCs

Photo taken from Jonathan A. Nowak/X

Oct 20, 2024, 17:11

Jonathan A. Nowak: KRAS G12C mutations are predictive of response in CRCs

Jonathan A. Nowak, Molecular and Gastrointestinal Pathologist at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, shared the following on X:

“KRAS G12C mutations occur in approximately 3-4% of CRCs and are predictive of response to combo EGFR and KRAS G12C inhibition. To characterize unique features of G12C-mutant CRC, we analyzed 1,347 CRCs in the Harvard NHS/HPFS cohorts. Read more.”

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation

Authors: Satoko Ugai, Qian Yao, Yasutoshi Takashima, Yuxue Zhong, Kosuke Matsuda, Hidetaka Kawamura, Yu Imamura, Kazuo Okadome, Kosuke Mima, Kota Arima, Keisuke Kosumi, Mingyang Song, Jeffrey A. Meyerhardt, Marios Giannakis, Jonathan A. Nowak, Tomotaka Ugai, Shuji Ogino.

Jonathan A. Nowak: KRAS G12C mutations are predictive of response in CRCs

Source: Jonathan A. Nowak/X

cancer Cancer research colorectal cancer CRC EGFR inhibition Harvard NHS Hidetaka Kawamura HPFS cohorts Jeffrey A Meyerhardt Jonathan A Nowak Kazuo Okadome Keisuke Kosumi Kosuke Matsuda Kosuke Mima Kota Arima KRAS G12C inhibition KRAS G12C mutations Marios Giannakis Mingyang Song OncoDaily Oncology Qian Yao Satoko Ugai Shuji Ogino Tomotaka Ugai Yasutoshi Takashima Yu Imamura Yuxue Zhong

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage